BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18500693)

  • 1. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results.
    van Gils MP; Hessels D; Hulsbergen-van de Kaa CA; Witjes JA; Jansen CF; Mulders PF; Rittenhouse HG; Schalken JA
    Prostate; 2008 Aug; 68(11):1215-22. PubMed ID: 18500693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer.
    Hessels D; van Gils MP; van Hooij O; Jannink SA; Witjes JA; Verhaegh GW; Schalken JA
    Prostate; 2010 Jan; 70(1):10-6. PubMed ID: 19708043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
    Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
    J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
    Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
    J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
    Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
    Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy.
    Durand X; Xylinas E; Radulescu C; Haus-Cheymol R; Moutereau S; Ploussard G; Forgues A; Robert G; Vacherot F; Loric S; Allory Y; Ruffion A; de la Taille A
    BJU Int; 2012 Jul; 110(1):43-9. PubMed ID: 22221521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
    Schmid M; Hansen J; Chun FK
    Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy.
    Cantiello F; Russo GI; Ferro M; Cicione A; Cimino S; Favilla V; Perdonà S; Bottero D; Terracciano D; De Cobelli O; Morgia G; Damiano R
    Urol Oncol; 2015 Apr; 33(4):163.e15-23. PubMed ID: 25575715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
    Hendriks RJ; van Oort IM; Schalken JA
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy.
    Wolters T; Vissers KJ; Bangma CH; Schröder FH; van Leenders GJ
    BJU Int; 2010 Jul; 106(2):280-6. PubMed ID: 19888978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
    Stephan C; Jung M; Rabenhorst S; Kilic E; Jung K
    Clin Chem Lab Med; 2015 Jun; 53(7):1109-18. PubMed ID: 25720086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients.
    Laitinen S; Martikainen PM; Tolonen T; Isola J; Tammela TL; Visakorpi T
    Int J Cancer; 2008 Feb; 122(3):595-602. PubMed ID: 17943722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
    Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
    Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopsy and radical prostatectomy pathological patterns influence Prostate cancer gene 3 (PCA3) score.
    De Luca S; Passera R; Bollito E; Milillo A; Scarpa RM; Papotti M; Coda R; Randone DF
    Anticancer Res; 2013 Oct; 33(10):4657-62. PubMed ID: 24123045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.
    Shen M; Chen W; Yu K; Chen Z; Zhou W; Lin X; Weng Z; Li C; Wu X; Tao Z
    Exp Mol Pathol; 2011 Feb; 90(1):97-100. PubMed ID: 20970419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine.
    Ferro M; Lucarelli G; Bruzzese D; Perdonà S; Mazzarella C; Perruolo G; Marino A; Cosimato V; Giorgio E; Tagliamonte V; Bottero D; De Cobelli O; Terracciano D
    Anticancer Res; 2015 Feb; 35(2):1017-23. PubMed ID: 25667489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
    Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
    J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is PCA3 score useful in preoperative staging of a single microfocus of prostate cancer diagnosed at saturation biopsy?
    Pepe P; Fraggetta F; Galia A; Aragona F
    Urol Int; 2012; 89(2):143-7. PubMed ID: 22868485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness.
    Augustin H; Mayrhofer K; Pummer K; Mannweiler S
    Prostate; 2013 Jan; 73(2):203-10. PubMed ID: 22782916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.